Literature DB >> 26837960

Applicability of RNA interference in cancer therapy: Current status.

S Maduri1.   

Abstract

Cancer is a manifestation of dysregulated gene function arising from a complex interplay of oncogenes and tumor suppressor genes present in our body. Cancer has been constantly chased using various therapies but all in vain as most of them are highly effective only in the early stages of cancer. Recently, RNA interference (RNAi) therapy, a comparatively new entrant is evolving as a promising player in the battle against cancer due to its post-transcriptional gene silencing ability. The most alluring feature of this non-invasive technology lies in its utility in the cancer detection and the cancer treatment at any stage. Once this technology is fully exploited it can bring a whole new era of therapeutics capable of curing cancer at any stage mainly due to its ability to target the vital processes required for cell proliferation such as response to growth factors, nutrient uptake/synthesis, and energy generation. This therapy can also be used to treat stage IV cancer, the most difficult to treat till date, by virtue of its metastasis inhibiting capability. Recent research has also proved that cancer can even be prevented by proper modulation of physiological RNAi pathways and researchers have found that many nutrients, which are a part of routine diet, can effectively modulate these pathways and prevent cancer. Even after having all these advantages the potential of RNAi therapy could not be fully tapped earlier, due to many limitations associated with the administration of RNAi based therapeutics. However, recent advancements in this direction, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi based therapeutics in the treatment of cancer. The present review focuses on the current status of RNAi therapeutics and explores their potential as future diagnostics and therapeutics against cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26837960     DOI: 10.4103/0019-509X.175598

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  6 in total

1.  Quantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells.

Authors:  Guimiao Lin; Ting Chen; Jinyun Zou; Yucheng Wang; Xiaomei Wang; Jiefeng Li; Qijun Huang; Zicai Fu; Yingying Zhao; Marie Chia-Mi Lin; Gaixia Xu; Ken-Tye Yong
Journal:  Front Pharmacol       Date:  2017-04-04       Impact factor: 5.810

2.  Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.

Authors:  Ming Sun; Zhaofu Chen; Shutao Tan; Caigang Liu; Wenyan Zhao
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

3.  The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells.

Authors:  Zhonglin Cao; Huiyu Xiao; Li Li; Maixian Liu; Guimiao Lin; Peng Zhai; Ken-Tye Yong; Xiaomei Wang; Gaixia Xu
Journal:  Front Pharmacol       Date:  2019-10-10       Impact factor: 5.810

4.  Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.

Authors:  Tímea Kiss; Krisztina Jámbor; Viktória Koroknai; István Szász; Helga Bárdos; Attila Mokánszki; Róza Ádány; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2021-03-05       Impact factor: 3.201

5.  MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells.

Authors:  Francesco Mainini; David S Larsen; Gill A Webster; Sarah L Young; Michael R Eccles
Journal:  Nucleic Acid Ther       Date:  2018-06-12       Impact factor: 5.486

6.  LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells.

Authors:  Quan-Jun Lin; Zhi-Bo Xie; Ya Gao; Yi-Fan Zhang; Lie Yao; De-Liang Fu
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.